{"id":"W2761767010","doi":"10.1093/annonc/mdx372","title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Placebo; Internal medicine; Quality of life (healthcare); Cohort; Ovarian cancer; Oncology; Adverse effect; Population; PARP inhibitor; Cancer; Gynecology; Poly ADP ribose polymerase; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009583667,0.0005390715,0.001242259,0.0001656166,0.0001712661,0.0007097959,0.0003799229,0.0004616402,0.001036554],"category_scores_gemma":[0.001257188,0.0001631816,0.001847732,0.0003529584,0.0004115374,0.0004278463,0.0003835846,0.001464235,0.0001447718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005651884,"about_ca_system_score_gemma":0.0004456122,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007543396,"about_ca_topic_score_gemma":0.001774214,"domain_scores_codex":[0.9996356,0.0001874452,0.00002892435,0.00005183983,0.00004272096,0.00005337371],"domain_scores_gemma":[0.9995366,0.0001199492,0.00016866,0.00003277315,0.00002431599,0.000117754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6584533,0.005071349,0.0914287,0.002611841,0.01445786,0.000271172,0.0002020418,0.003636707,0.005607866,0.000424338,0.004629219,0.2132057],"study_design_scores_gemma":[0.4098547,0.1320515,0.42247,0.0005621995,0.01538574,0.00105432,0.0003288535,0.003997921,0.001982856,0.002115062,0.01007199,0.0001248057],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827294,0.01432916,0.0001164875,0.0005681412,0.0001327396,0.0001322042,0.0006805388,0.00001435458,0.001296992],"genre_scores_gemma":[0.9928656,0.004397441,0.0002160125,0.0004681306,0.0001296086,0.000124928,0.001315184,0.0000052392,0.0004778889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001242259,"threshold_uncertainty_score":0.005068421,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2359279411293708,"score_gpt":0.4583244443639273,"score_spread":0.2223965032345565,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}